《股市简讯》中国生物制药升3%，TQH2722注射液新药上市申请获得受理

路透中文

昨天

《股市简讯》<a href="https://laohu8.com/S/01177">中国生物制药</a>升3%，TQH2722注射液新药上市申请获得受理

* 泰国富豪谢氏家族旗下制药公司--中国生物制药1177.HK周三早盘一度升3%，TQH2722注射液新药上市申请获得受理。

* 该公司公告称，附属公司正大天晴药业集团自主研发的国家1类创新药TQH2722注射液“IL4Rα单抗”已向中国国家药品监督管理局药品审评中心（CDE）递交新药上市申请并获得受理，用于外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎$(AD)$。

* 中国生物制药今年迄今跌10.2%，同期恒生指数.HSI累跌3.9%。

* 恒生生物科技指数.HSBIO盘中跌0.3%。（完）

更多股市简讯请点选CN-CMN-HOT

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2667767156"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667767156\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667767156?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-09-16 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667767156","market":"us","top_or_hot":-1,"title":"《股市简讯》中国生物制药升3%，TQH2722注射液新药上市申请获得受理","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市简讯》<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>升3%，TQH2722注射液新药上市申请获得受理</title></head><body><p>* 泰国富豪谢氏家族旗下制药公司--中国生物制药<span>1177.HK</span>周三早盘一度升3%，TQH2722注射液新药上市申请获得受理。</p><p>* 该公司<span>公告</span>称，附属公司正大天晴药业集团自主研发的国家1类创新药TQH2722注射液“IL4Rα单抗”已向中国国家药品监督管理局药品审评中心（CDE）递交新药上市申请并获得受理，用于外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎<a href=\"https://laohu8.com/S/AD\">$(AD)$</a>。</p><p>* 中国生物制药今年迄今跌10.2%，同期恒生指数<span>.HSI</span>累跌3.9%。</p><p>* 恒生生物科技指数<span>.HSBIO</span>盘中跌0.3%。（完）</p><p>\n        更多股市简讯请点选<span>CN-CMN-HOT</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《股市简讯》中国生物制药升3%，TQH2722注射液新药上市申请获得受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《股市简讯》中国生物制药升3%，TQH2722注射液新药上市申请获得受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-09-16 10:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市简讯》<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>升3%，TQH2722注射液新药上市申请获得受理</title></head><body><p>* 泰国富豪谢氏家族旗下制药公司--中国生物制药<span>1177.HK</span>周三早盘一度升3%，TQH2722注射液新药上市申请获得受理。</p><p>* 该公司<span>公告</span>称，附属公司正大天晴药业集团自主研发的国家1类创新药TQH2722注射液“IL4Rα单抗”已向中国国家药品监督管理局药品审评中心（CDE）递交新药上市申请并获得受理，用于外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎<a href=\"https://laohu8.com/S/AD\">$(AD)$</a>。</p><p>* 中国生物制药今年迄今跌10.2%，同期恒生指数<span>.HSI</span>累跌3.9%。</p><p>* 恒生生物科技指数<span>.HSBIO</span>盘中跌0.3%。（完）</p><p>\n        更多股市简讯请点选<span>CN-CMN-HOT</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nL4S45804G:1","article_id":"2667767156","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667767156","pubTimestamp":1789524890,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"《股市简讯》中国生物制药升3%，TQH2722注射液新药上市申请获得受理* 泰国富豪谢氏家族旗下制药公司--中国生物制药1177.HK周三早盘一度升3%，TQH2722注射液新药上市申请获得受理。* 该公司公告称，附属公司正大天晴药业集团自主研发的国家1类创新药TQH2722注射液“IL4Rα单抗”已向中国国家药品监督管理局药品审评中心递交新药上市申请并获得受理，用于外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1589":"北水核心资产","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1515":"抗疫概念","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","01177":"中国生物制药","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC"},"translate_title":"\"Stock Market Brief\" China Biopharmaceuticals rose 3%, TQH2722 injection new drug listing application accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9},"content_text":"《股市简讯》<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>升3%，TQH2722注射液新药上市申请获得受理* 泰国富豪谢氏家族旗下制药公司--中国生物制药1177.HK周三早盘一度升3%，TQH2722注射液新药上市申请获得受理。* 该公司公告称，附属公司正大天晴药业集团自主研发的国家1类创新药TQH2722注射液“IL4Rα单抗”已向中国国家药品监督管理局药品审评中心（CDE）递交新药上市申请并获得受理，用于外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎$(AD)$。* 中国生物制药今年迄今跌10.2%，同期恒生指数.HSI累跌3.9%。* 恒生生物科技指数.HSBIO盘中跌0.3%。（完）\n        更多股市简讯请点选CN-CMN-HOT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}